Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8196122 | 0.91 | ACHE (0.32) | ACHE | |
| SCHEMBL1629925 | 0.83 | PHGDH (0.42) | PHGDHMGLLCARM1PRMT6PRMT1 | |
| SCHEMBL2356063 | 0.76 | HIF1A (0.42) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL10982018 | 0.75 | ACHE (0.41) | PHGDHMGLLCARM1PRMT6PRMT1 | |
| SCHEMBL7571755 | 0.74 | GNAI3 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL28420298 | 0.73 | GUSB (0.31) | — | |
| SCHEMBL28420301 | 0.73 | GUSB (0.31) | — | |
| SCHEMBL12912807 | 0.73 | NCF1 (0.33) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL22970443 | 0.73 | CARM1 (0.52) | CARM1PRMT6PRMT1PRMT8ACHE | |
| SCHEMBL18666762 | 0.73 | ACHE (0.42) | PHGDHMGLLCARM1PRMT6PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43098-E1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | claimed |
| US-6951937-B2 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-04 | — | — | US | claimed |
| CN-114423750-B | 2, 4-Disubstituted pyrimidine derivative, preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-114423750-A | 2, 4-disubstituted pyrimidine derivative and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3309162-A1 | TARGETED CONJUGATES OF PYRROLOBENZODIAZEPINES | Seattle Genetics, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| EP-1548121-B1 | Physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2015-04-29 | — | — | EP | disclosed |
| CN-1671856-B | Novel physiologically active substances | EISAI R&D MAN CO LTD | 2010-05-12 | — | — | CN | disclosed |
| US-7256178-B2 | Physiologically active substances | EISAI CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |
| US-20050245514-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| CN-1671856-A | Novel physiologically active substances | MERCIAN CORP (JP) | 2005-09-21 | — | — | CN | disclosed |
| EP-1548121-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-4148895-A | HYPOTENSIVE, ANTIARRHYMIA AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245514-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | CHRNB2 4516/4885CHRNA3 4519/4885CHRNA4 4636/4885 |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | ENPP2, ATXN2, ATXN2L | CHRNB2 465/4885CHRNA3 832/4885CHRNA4 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.